Ghana is set to benefit from an improved foreign exchange following the discovery of a new injectable cancer medication by the COA Research and Manufacturing Limited.
Chief Executive Officer (CEO) of COA Research and Manufacturing Limited, Prof Samuel Ato Duncan says the new product line is expected to revolutionize Ghana’s pharmaceutical landscape.
Prof. Ato Duncan made this revelation following a working visit paid by the Asantehene Otumfuo Osei Tutu to the facility of COA at Wusorkrom, located in the Abura Asebu Kwamankese District in the Central Region.
This groundbreaking injectable medication which will treat cancer and other viruses, Prof. Ato Duncan said is currently under research and forms part of the four new products the company is anticipating to introduce to the local and international market.
He further revealed that the production factory that will be dedicated to this new medication will be constructed in the Ashanti Region on a parcel of land provided by the Asantehene.
The US$ 50 million estimated annual revenue is expected to revolutionize the company and expand its market reach in addition to enhancing Ghana’s economic growth.
COA Research and Manufacturing Limited has over the years gained national and international recognition. This follows the production of COA FX and later shifts focus to COA Mixture, a 100% herbal product that plays a critical role in combating COVID-19.
The enhanced formula, COA Plus, offers additional immune support, while COA Malaria Typhoid (MT) Mixture, made from the Nim tree, has been developed to treat malaria.
Prof. Ato Duncan revealed plans for COA Capsules which have been approved by Ghana’s Food and Drugs Authority (FDA) but not yet commercially produced, along with COA Energy water, COA Balm, and COA Ointment.
